Project

Trial SAKK 19/17: First line durvalumab in patients with PD-L1 positve, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial

Ongoing - recruitment closed · 2018 until 2099

Früh Martin, Breuss Kim, Quinter Janine